X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA CIPLA SHASUN PHARMA/
CIPLA
 
P/E (TTM) x 123.9 34.0 364.9% View Chart
P/BV x 8.5 3.0 288.4% View Chart
Dividend Yield % 0.2 0.6 40.7%  

Financials

 SHASUN PHARMA   CIPLA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
CIPLA
Mar-18
SHASUN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs94663 14.2%   
Low Rs46479 9.5%   
Sales per share (Unadj.) Rs214.2189.0 113.3%  
Earnings per share (Unadj.) Rs5.317.6 30.3%  
Cash flow per share (Unadj.) Rs15.834.0 46.5%  
Dividends per share (Unadj.) Rs1.003.00 33.3%  
Dividend yield (eoy) %1.40.5 272.3%  
Book value per share (Unadj.) Rs53.3176.7 30.2%  
Shares outstanding (eoy) m56.62805.12 7.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 10.8%   
Avg P/E ratio x13.132.5 40.4%  
P/CF ratio (eoy) x4.416.8 26.3%  
Price / Book Value ratio x1.33.2 40.6%  
Dividend payout %18.717.1 109.9%   
Avg Mkt Cap Rs m3,958459,724 0.9%   
No. of employees `000NA23.6 0.0%   
Total wages/salary Rs m2,16426,901 8.0%   
Avg. sales/employee Rs ThNM6,446.1-  
Avg. wages/employee Rs ThNM1,139.4-  
Avg. net profit/employee Rs ThNM600.0-  
INCOME DATA
Net Sales Rs m12,127152,193 8.0%  
Other income Rs m2293,577 6.4%   
Total revenues Rs m12,356155,769 7.9%   
Gross profit Rs m1,00928,264 3.6%  
Depreciation Rs m59413,228 4.5%   
Interest Rs m4151,142 36.3%   
Profit before tax Rs m23017,470 1.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 1.1%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m-732,501 -2.9%   
Profit after tax Rs m30214,166 2.1%  
Gross profit margin %8.318.6 44.8%  
Effective tax rate %-31.714.3 -221.1%   
Net profit margin %2.59.3 26.8%  
BALANCE SHEET DATA
Current assets Rs m6,884108,141 6.4%   
Current liabilities Rs m8,45638,322 22.1%   
Net working cap to sales %-13.045.9 -28.2%  
Current ratio x0.82.8 28.9%  
Inventory Days Days6297 63.5%  
Debtors Days Days10874 144.5%  
Net fixed assets Rs m4,970109,411 4.5%   
Share capital Rs m1131,610 7.0%   
"Free" reserves Rs m2,875140,682 2.0%   
Net worth Rs m3,020142,292 2.1%   
Long term debt Rs m1,81736,621 5.0%   
Total assets Rs m13,347228,606 5.8%  
Interest coverage x1.616.3 9.5%   
Debt to equity ratio x0.60.3 233.8%  
Sales to assets ratio x0.90.7 136.5%   
Return on assets %5.46.7 80.2%  
Return on equity %10.010.0 100.5%  
Return on capital %13.310.0 133.8%  
Exports to sales %46.432.8 141.4%   
Imports to sales %14.20-   
Exports (fob) Rs m5,62249,883 11.3%   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84351,691 11.3%   
Fx outflow Rs m2,17321,033 10.3%   
Net fx Rs m3,66930,658 12.0%   
CASH FLOW
From Operations Rs m39814,628 2.7%  
From Investments Rs m-1,635-8,540 19.1%  
From Financial Activity Rs m1,309-3,855 -33.9%  
Net Cashflow Rs m712,431 2.9%  

Share Holding

Indian Promoters % 39.2 16.0 245.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 3.6 12.2 29.5%  
FIIs % 17.6 23.7 74.3%  
ADR/GDR % 0.0 1.1 -  
Free float % 39.6 26.2 151.1%  
Shareholders   20,750 161,166 12.9%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  STRIDES PHARMA SCIENCE  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare SHASUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open on a Positive Note; Realty & Auto Stocks Lead(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.2% while the Hang Seng is up 1.6%.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS